Sygnature Discovery has announced strategic collaboration with DaltonTx, an Artificial Intelligence (AI) technology company, to further strengthen its AI-enabled drug discovery capabilities. This collaboration is designed to accelerate medicinal chemistry decision-making while ensuring the highest standards of data security for its customers.

DaltonTx brings together expertise in drug discovery, software engineering, and AI through its Dalton platform, which integrates data, models and experimental results into a unified environment to support biologics and small molecule discovery programs.

Through this collaboration, Sygnature Discovery is integrating DaltonTx into our existing computational and medicinal chemistry toolkit alongside proprietary and third-party technologies, including SygDesign, BullFrog AI, and Iktos. By combining these complementary AI platforms, we aim to enable faster, more informed decision-making across our discovery programs.

As part of this collaboration, we are conducting a retrospective evaluation using a legacy oncology program focused on a small molecule clinical candidate currently in phase 1 development. This analysis is assessing whether the Dalton platform could have enabled us to reach candidate selection more efficiently through improved decision-making and a reduced synthesis burden.

Simon Hirst, CEO, Sygnature Discovery, said, “AI in drug discovery continues to evolve rapidly, but we believe the future lies in combining the power of Machine Learning with the expertise and intuition of experienced scientists. By helping scientists make better-informed decisions earlier in the discovery process, we can reduce the number of compounds synthesised and tested, shorten DMTA cycles, and accelerate progression toward candidate selection.”

Unlike many standalone AI applications, Dalton combines a secure and scalable backend architecture with a natural language interface powered by agentic AI technologies, enabling scientists to drive ideation and problem-solving through conversational workflows.

Garry Pairaudeau, CEO and Co-Founder, DaltonTx, said, “The next phase of AI in drug discovery is about impact. We believe the organisations that capture the most value from AI will be those that connect their teams, tools and data into systems that improve real-world discovery decisions. Dalton unifies data, models, and experimental results to capture what worked, what failed and why, with full context so judgement compounds over time. We are proud to collaborate with Sygnature Discovery to deliver tangible outcomes that translate into measurable value.”

This collaboration also addresses growing industry concerns around the use of proprietary data in AI-enabled environments. We ensure that customer data and AI models are compartmentalised on a per-program basis, so that customer information is never used to train models supporting other projects.

“Our approach ensures our customers can access the latest AI-enabled technologies without their data being used to train models for the benefit of others. We have well-established systems in place to securely manage customer data, and those same principles apply when deploying AI tools,” added Hirst.

We plan to extend validation of the Dalton platform into live customer programs as opportunities arise.